Septerna reports FY2024 net loss of $71.8M, discontinues SEP-786 Phase 1 trial

Septerna, Inc.

Discontinued SEP-786 Phase 1 trial after two Grade 3 elevated unconjugated bilirubin events, reversible without liver injury.
Plans to select a next-generation oral PTH1R agonist candidate by end of 2025 to advance toward clinic.
SEP-631 MRGPRX2 NAM program on track to initiate Phase 1 trial in 2025 for mast cell diseases.
Cash, equivalents, and marketable securities $420.8M at Dec 31, 2024; runway into early 2028.
Appointed Gil Labrucherie as CFO in January 2025; net loss $20.7M in Q4 2024, $71.8M for FY2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.